论文部分内容阅读
我院自1996年始应用思密达治疗肠道易激综合征中以腹泻为主的病人40例,收效明显,现报道如下:1 临床资料 本组诊断均符合全国慢性腹泻学术会议制定的IBS诊断标准。经纤维结肠镜检查,除外肿瘤、溃疡、息肉及各种炎症性肠病等器质性疾病。年龄18岁～65岁,男30例,女10例,病程3个月以上,腹痛以脐周为主,呈胀痛或隐痛,腹泻以每日排便在3次以上,多为稀便或伴有粘液样便。随机分为治疗组及对照组各20例,治疗期间停用其他影响观察的药物。2 治疗方法 治疗组服用思密达,每次3g,每日3次;对照组服用丽珠得乐,每次2粒,每日3次,30d为1疗程。3 疗效标准与结果 显效:临床症状消失,排便次数及便性状正常;有效:症状明显改善,便次明显减少,便性状正常;无效:症状无缓解或缓解不明显,排便性状
Our hospital since 1996, the application of Smecta treatment of irritable bowel syndrome in diarrhea-based patients in 40 cases, the effect is obvious, are reported as follows: 1 Clinical data The diagnosis of this group are in line with the national conference of chronic diarrhea IBS diagnosis standard. Colonoscopy by fiber, except tumors, ulcers, polyps and various inflammatory bowel disease and other organic diseases. Age 18 years old to 65 years old, 30 males and 10 females, duration of 3 months or more, abdominal pain mainly in the umbilical week, was pain or pain, diarrhea daily defecation at least 3 times, mostly loose stools or companion There is mucoid like. Randomly divided into treatment group and control group of 20 cases, disable the other effects observed during the treatment of drugs. 2 treatment group treated with Smectite, each 3g, 3 times a day; the control group taking Livudol, 2 capsules each time, 3 times a day, 30d for a course of treatment. 3 efficacy standards and the results markedly: the disappearance of clinical symptoms, defecation frequency and normal trait; effective: significantly improved, then significantly reduced, then the trait is normal; invalid: no symptoms or ease of remission is not obvious, defecation traits